Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

The Outcome of Mantle Cell Lymphoma patients after Treatment Failure and Prognostic value of Secondary Mantle Cell International Prognostic Index (sec MIPI)

Marek Trneny, MD, Pavel Klener, MD, David Belada, MD, Heidi Mocikova, MD, PhD, Vit Prochazka, MD, Samuel Vokurka, MD PhD, Jan Pirnos, MD, Katerina Kubackova, MD, Juraj Duras, MD, Jana Salkova, MD, David Salek, MD, Robert Pytlik, MD, PhD, Lucie Barsova, MD, Petr Kessler, MD, Ludmila Boudova, MD, Vit Campr, MD, PhD, Radek Jaksa, MD, Jitka Dlouha, Katerina Benesova, MD

Blood (2014) 124 (21): 4425.

https://doi.org/10.1182/blood.V124.21.4425.4425

Published: 2014

Journal Articles

Median Absolute Lymphocyte Count Independently Predicts Survival of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-Chemotherapy: Analysis of 651 Patients Included In the Czech Lymphoma Project

Blood (2010) 116 (21): 2882.

https://doi.org/10.1182/blood.V116.21.2882.2882

Published: 2010

Journal Articles

The Rituximab Treament for Relapsed Follicular Lymphomas Changes the Duration of Subsequent Responses. the Analysis on Behalf of CLSG

Marek Trneny, MD, PhD, Robert Pytlik, MD, David Belada, MD, PhD., Katerina Kubackova, MD, Milada Jankovska, MD, Tomas Papajik, MD., PhD., Jan Pirnos, MD, Hana Krejcova

Blood (2008) 112 (11): 1014.

https://doi.org/10.1182/blood.V112.11.1014.1014

Published: 2008

Journal Articles

Mantle Cell Lymphoma International Prognostic Score Is Valid and Confirmed in Unselected Cohort of Patients Treated in Rituximab Era

David Salek, MD, Ingrid Vasova, MD, Robert Pytlik, MD, David Belada, MD, PhD, Tomas Papajik, MD, PhD, Katerina Kubackova, MD, Jan Pirnos, MD, Ludmila Boudova, MD, PhD, Roman Kodet, MD, Petra Obrtlikova, MD, Hana Krejcova, Marek Trneny, MD, PhD

Blood (2008) 112 (11): 3745.

https://doi.org/10.1182/blood.V112.11.3745.3745

Published: 2008

Journal Articles

Treatment of Diffuse Large B-Cell Lymphoma with Rituximab, Intensive Induction and High-Dose Consolidation: The Final Analysis of the Czech Lymphoma Study Group (CLSG) R-MegaCHOP-ESHAP-BEAM (R-MEB) Trial.

Marek Trneny, Robert Pytlik, David Belada, Katerina Kubackova, Ingrid Vasova, Alice Sykorova, Tomas Kozak, Jan Pirnos, Milan Matuska, Ingrid Bolomska, Jana Pribylova, Marie Trnkova, Michaela Hamouzova, Pavel Klener

Blood (2007) 110 (11): 21.

https://doi.org/10.1182/blood.V110.11.21.21

Published: 2007

Journal Articles

Intensive Induction Is Beneficial for High Risk Younger Patients with Aggressive B-Cell Lymphoma, While Frontline ASCT Brings No Benefit: Final Analysis of MegaCHOP-BEAM and MegaCHOP-ESHAP-BEAM Studies.

Robert Pytlik, David Belada, Katerina Kubackova, Tomas Kozak, PhD, Milada Jankovska, Jan Pirnos, Ingrid Bolomska, Ingrid Vasova, Tomas Papajik, Alena Sykorova, Hana Siffnerova, Michaela Hamouzova, Pavel Klener, Marek Trneny

Blood (2006) 108 (11): 4692.

https://doi.org/10.1182/blood.V108.11.4692.4692

Published: 2006

Journal Articles

Treatment of High Risk Diffuse Large B-Cell Lymphomas (DLBCL) with Ntensive Induction Chemotherapy, Rituximab and Autologous Stem Cell Transplant.

Robert Pytlik, Marek Trneny, David Belada, Jan Pirnos, Katerina Kubackova, Milada Jankovska, Ingrid Vasova, Tomas Kozak, Jana Pukyova, Jana Pribylova, Hana Siffnerova, Pavel Zak, Michaela Hamouzova, Pavel Klener

Blood (2005) 106 (11): 1506.

https://doi.org/10.1182/blood.V106.11.1506.1506

Published: 2005

Journal Articles

Rituximab Combination with Anthracyclin Based Chemothrapy Significantly Improved the Outcome of Young Patients with Diffuse Large B-Cell Lymphoma in Low as Well in High Risk Subgroups.

Marek Trneny, MD, David Belada, MD, Ingrid Vasova, MD, Robert Pytlik, MD, Tomas Kozak, MD, Alice Sykorova, MD, Katerina Kubackova, MD, Jan Pirnos, MD, Ingrid Bolomska, MD, Marketa Petrova, Ing

Blood (2005) 106 (11): 2444.

https://doi.org/10.1182/blood.V106.11.2444.2444

Published: 2005

NARROW

The Outcome of Mantle Cell Lymphoma patients after Treatment Failure and Prognostic value of Secondary Mantle Cell International Prognostic Index (sec MIPI)

Median Absolute Lymphocyte Count Independently Predicts Survival of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-Chemotherapy: Analysis of 651 Patients Included In the Czech Lymphoma Project

The Rituximab Treament for Relapsed Follicular Lymphomas Changes the Duration of Subsequent Responses. the Analysis on Behalf of CLSG

Mantle Cell Lymphoma International Prognostic Score Is Valid and Confirmed in Unselected Cohort of Patients Treated in Rituximab Era

Treatment of Diffuse Large B-Cell Lymphoma with Rituximab, Intensive Induction and High-Dose Consolidation: The Final Analysis of the Czech Lymphoma Study Group (CLSG) R-MegaCHOP-ESHAP-BEAM (R-MEB) Trial.

Intensive Induction Is Beneficial for High Risk Younger Patients with Aggressive B-Cell Lymphoma, While Frontline ASCT Brings No Benefit: Final Analysis of MegaCHOP-BEAM and MegaCHOP-ESHAP-BEAM Studies.

Treatment of High Risk Diffuse Large B-Cell Lymphomas (DLBCL) with Ntensive Induction Chemotherapy, Rituximab and Autologous Stem Cell Transplant.

Rituximab Combination with Anthracyclin Based Chemothrapy Significantly Improved the Outcome of Young Patients with Diffuse Large B-Cell Lymphoma in Low as Well in High Risk Subgroups.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only